
|Videos|January 31, 2019
Combining BRAF, MEK and EGFR Inhibition in mCRC
Advertisement
Experts review the scientific rationale for combining BRAF, MEK and EGFR inhibition in BRAF-mutated mCRC; a strategy tested in such settings as the ANCHOR and BEACON trials.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5



































